State Street’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-548,743
| Closed | -$4.96M | – | 4347 |
|
|
2025
Q4 | $4.96M | Buy |
548,743
+261,002
| +91% | +$1.95M | ﹤0.01% | 2996 |
|
|
2025
Q3 | $895K | Buy |
287,741
+1,299
| +0.5% | +$3.44K | ﹤0.01% | 3538 |
|
|
2025
Q2 | $613K | Sell |
286,442
-958,010
| -77% | -$1.55M | ﹤0.01% | 3581 |
|
|
2025
Q1 | $1.43M | Buy |
1,244,452
+29,540
| +2% | +$50.7K | ﹤0.01% | 3349 |
|
|
2024
Q4 | $2.66M | Buy |
1,214,912
+27,262
| +2% | +$61.8K | ﹤0.01% | 3224 |
|
|
2024
Q3 | $2.59M | Buy |
1,187,650
+9,783
| +0.8% | +$22.5K | ﹤0.01% | 3236 |
|
|
2024
Q2 | $2.72M | Buy |
1,177,867
+251,278
| +27% | +$1.04M | ﹤0.01% | 3197 |
|
|
2024
Q1 | $5.1M | Sell |
926,589
-63,834
| -6% | -$292K | ﹤0.01% | 2917 |
|
|
2023
Q4 | $2.45M | Sell |
990,423
-106,096
| -10% | -$1.01M | ﹤0.01% | 3248 |
|
|
2023
Q3 | $38.1M | Buy |
1,096,519
+56,421
| +5% | +$1.95M | ﹤0.01% | 1790 |
|
|
2023
Q2 | $34.1M | Buy |
1,040,098
+440,271
| +73% | +$15.2M | ﹤0.01% | 1891 |
|
|
2023
Q1 | $20.1M | Buy |
599,827
+47,821
| +9% | +$1.86M | ﹤0.01% | 2224 |
|
|
2022
Q4 | $18.1M | Buy |
552,006
+111,063
| +25% | +$3.29M | ﹤0.01% | 2313 |
|
|
2022
Q3 | $15.4M | Buy |
440,943
+115,607
| +36% | +$2.56M | ﹤0.01% | 2413 |
|
|
2022
Q2 | $3.98M | Buy |
325,336
+154,141
| +90% | +$2.3M | ﹤0.01% | 3207 |
|
|
2022
Q1 | $2.32M | Buy |
171,195
+67,590
| +65% | +$903K | ﹤0.01% | 3504 |
|
|
2021
Q4 | $2.06M | Buy |
+103,605
| New | +$1.96M | ﹤0.01% | 3631 |
|
Other funds holding VTYX
State Street's VTYX Position: Q1 2026 in Review
State Street sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 548,743 shares — an estimated $4.96M sold.
State Street first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $38.1M in Q3 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- State Street reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- State Street sold 548,743 Ventyx Biosciences shares in Q1 2026, an estimated $4.96M.
- State Street first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
- State Street's Ventyx Biosciences position peaked at $38.1M in Q3 2023.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.